

Bayer Iceland 2024 [ISK]												Date of Publication: 27/06/2025	
	Full Name <i>(Art. 1.01)</i>	HCPs: City of Principal Practice HCOs: city where registered <i>(Art. 3)</i>	Country of Principal Practice <i>(Schedule 1)</i>	Principal Practice Address <i>(Art. 3)</i>	Unique country identifier <i>(Art. 3)</i>	Donations and Grants to HCOs <i>(Art. 3.01.1.a)</i>	Contribution to costs of Events <i>(Art. 3.01.1.b & 3.01.2.a)</i>			Fee for service and consultancy <i>(Art. 3.01.1.c & 3.01.2.c)</i>			
							Sponsorship agreements with HCOs / third parties appointed by HCOs to manage an Event	Registration Fees	Travel & Accommodation	Fees	Related expenses agreed in the fee for service or consultancy contract, including travel & accommodation relevant to the contract		
HCPs	INDIVIDUAL NAMED DISCLOSURE - one line per HCP (i.e. all transfers of value during a year for an individual HCP will be summed up: itemization should be available for the individual Recipient or public authorities' consultation only, as appropriate)												
HCPs	Aggregate amount attributable to transfers of value to such Recipients - <i>Art. 3.02</i>						No Data for 2024						
	Number of Recipients in aggregate disclosure - <i>Art. 3.02</i>												
	% of the number of Recipients included in the aggregate disclosure in the total number of Recipients disclosed - <i>Art. 3.02</i>												
HCOs	INDIVIDUAL NAMED DISCLOSURE - one line per HCO (i.e. all transfers of value during a year for an individual HCO will be summed up: itemization should be available for the individual Recipient or public authorities' consultation only, as appropriate)												
HCOs	Aggregate amount attributable to transfers of value to such Recipients - <i>Art. 3.02</i>						No Data for 2024						
	Number of Recipients in aggregate disclosure - <i>Art. 3.02</i>												
	% of the number of Recipients included in the aggregate disclosure in the total number of Recipients disclosed - <i>Art. 3.02</i>												
R & D	AGGREGATE DISCLOSURE												
	Transfers of Value Research & Development as defined - <i>Article 3.04 and Schedule 1</i>												

This report is relevant for Bayer cross-country transfers of value to Icelandic healthcare professionals and organizations

Transfers of values for Bayer to Icelandic healthcare professionals and organizations done in Iceland are published here: <https://frumtok.is/en/codes-and-ethics/>